Related Experiment Video
Updated: Jul 30, 2025
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
Neonatal Hyperbilirubinemia: Evaluation and Treatment
Emma J Par1, Chase A Hughes2, Pierce DeRico3
1Duke University School of Medicine, Durham, North Carolina.
Insights
Neonatal jaundice, or hyperbilirubinemia, is common. New guidelines suggest universal screening may increase unnecessary phototherapy, emphasizing individualized treatment based on risk factors and bilirubin levels.
Area of Science:
- Neonatal Medicine
- Pediatrics
- Clinical Practice Guidelines
Background:
- Neonatal jaundice due to hyperbilirubinemia is a common condition, typically benign.
- Kernicterus, a rare but severe form of brain damage, occurs at higher bilirubin levels than previously thought, especially in premature infants or those with hemolytic diseases.
Purpose of the Study:
- To evaluate the effectiveness of universal neonatal hyperbilirubinemia screening.
- To analyze the updated 2022 American Academy of Pediatrics (AAP) clinical practice guidelines.
- To assess the risks and benefits of phototherapy in managing neonatal jaundice.
Main Methods:
- Review of the 2022 AAP clinical practice guideline for neonatal hyperbilirubinemia.
- Analysis of evidence regarding kernicterus incidence and bilirubin thresholds.
- Evaluation of phototherapy's impact on exchange transfusion rates and adverse effects.
Main Results:
- Universal screening may lead to increased unnecessary phototherapy without proven reduction in kernicterus.
- New AAP nomograms recommend higher phototherapy thresholds based on gestational age and risk factors.
- Phototherapy, while reducing exchange transfusions, carries potential adverse effects and can disrupt breastfeeding.
Conclusions:
- Individualized assessment of risk factors and bilirubin levels is crucial for managing neonatal jaundice.
- Phototherapy should be reserved for newborns exceeding current AAP hour-specific nomogram thresholds.
- Further evidence is needed to support universal screening's benefit in reducing kernicterus incidence.
Abstract:
Neonatal jaundice due to hyperbilirubinemia is common, and most cases are benign. The irreversible outcome of brain damage from kernicterus is rare (1 out of 100,000 infants) in high-income countries such as the United States, and there is increasing evidence that kernicterus occurs at much higher bilirubin levels than previously thought. However, newborns who are premature or have hemolytic diseases are at higher risk of kernicterus. It is important to evaluate all newborns for risk factors for bilirubin-related neurotoxicity, and it is reasonable to obtain screening bilirubin levels in newborns with risk factors. All newborns should be examined regularly, and bilirubin levels should be measured in those who appear jaundiced. The American Academy of Pediatrics (AAP) revised its clinical practice guideline in 2022 and reconfirmed its recommendation for universal neonatal hyperbilirubinemia screening in newborns 35 weeks' gestational age or greater. Although universal screening is commonly performed, it increases unnecessary phototherapy use without sufficient evidence that it decreases the incidence of kernicterus. The AAP also released new nomograms for initiating phototherapy based on gestational age at birth and the presence of neurotoxicity risk factors, with higher thresholds than in previous guidelines. Phototherapy decreases the need for an exchange transfusion but has the potential for short- and long-term adverse effects, including diarrhea and increased risk of seizures. Mothers of infants who develop jaundice are also more likely to stop breastfeeding, even though discontinuation is not necessary. Phototherapy should be used only for newborns who exceed thresholds recommended by the current AAP hour-specific phototherapy nomograms.
